Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating 16 vs 24 weeks of Daclatasvir/Sofosbuvir/Ribavirin in genotype 3 hepatitis C cirrhotics; completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatitis C

Drugs mentioned

• Daclatasvir/Sofosbuvir/Ribavirin

Snippet

Sponsor: Tarek I. Hassanein, M.D., FACP, FAG, AGAF | Conditions: Hepatitis C, Cirrhosis | Phase 4 | Status: COMPLETED | Results posted: 2019-04-24